[{"id":"8e698f4d-2a78-42c5-a620-76e572d7431e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595059","created_at":"2021-01-18T17:40:37.713Z","updated_at":"2024-07-02T16:35:05.958Z","phase":"Phase 1","brief_title":"A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors","source_id_and_acronym":"NCT03595059","lead_sponsor":"AbbVie","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 07/13/2018","start_date":" 07/13/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-03"}]